CO2024012060A2 - Derivados de espiro piperidina como inhibidores de apol1 y métodos para usarlos - Google Patents
Derivados de espiro piperidina como inhibidores de apol1 y métodos para usarlosInfo
- Publication number
- CO2024012060A2 CO2024012060A2 CONC2024/0012060A CO2024012060A CO2024012060A2 CO 2024012060 A2 CO2024012060 A2 CO 2024012060A2 CO 2024012060 A CO2024012060 A CO 2024012060A CO 2024012060 A2 CO2024012060 A2 CO 2024012060A2
- Authority
- CO
- Colombia
- Prior art keywords
- apol1
- methods
- inhibitors
- tautomers
- pharmaceutically acceptable
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
- C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263307926P | 2022-02-08 | 2022-02-08 | |
| PCT/US2023/012583 WO2023154314A1 (en) | 2022-02-08 | 2023-02-08 | Spiro piperidine derivatives as inhibitors of apol1 and methods of using same |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO2024012060A2 true CO2024012060A2 (es) | 2024-09-30 |
Family
ID=85415293
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CONC2024/0012060A CO2024012060A2 (es) | 2022-02-08 | 2024-09-04 | Derivados de espiro piperidina como inhibidores de apol1 y métodos para usarlos |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20250195483A1 (https=) |
| EP (1) | EP4476207A1 (https=) |
| JP (1) | JP2025505645A (https=) |
| CN (1) | CN119212986A (https=) |
| AU (1) | AU2023218940A1 (https=) |
| CA (1) | CA3251155A1 (https=) |
| CO (1) | CO2024012060A2 (https=) |
| WO (1) | WO2023154314A1 (https=) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11618746B2 (en) | 2018-12-17 | 2023-04-04 | Vertex Pharmaceuticals Incorporated | Inhibitors of APOL1 and methods of using same |
| WO2021154997A1 (en) | 2020-01-29 | 2021-08-05 | Vertex Pharmaceuticals Incorporated | Inhibitors of apol1 and methods of using same |
| CN115867543A (zh) | 2020-06-12 | 2023-03-28 | 弗特克斯药品有限公司 | Apol1抑制剂的固体形式及其使用方法 |
| CA3185604A1 (en) | 2020-06-12 | 2021-12-16 | Vertex Pharmaceuticals Incorporated | Inhibitors of apol1 and use of the same |
| CN116547287B (zh) | 2020-08-26 | 2025-09-26 | 弗特克斯药品有限公司 | Apol1的抑制剂及其使用方法 |
| US12612379B2 (en) | 2021-11-30 | 2026-04-28 | Vertex Pharmaceuticals Incorporated | Inhibitors of APOL1 and methods of using same |
| MX2024008868A (es) * | 2022-01-18 | 2024-09-23 | Maze Therapeutics Inc | Inhibidores de la apolipoproteína l1 (apol1) y métodos de uso. |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8222288B2 (en) * | 2006-08-30 | 2012-07-17 | The Regents Of The University Of Michigan | Small molecule inhibitors of MDM2 and the uses thereof |
| BRPI0721138A2 (pt) * | 2006-12-22 | 2014-04-01 | Hoffmann La Roche | Derivados de espiro-piperidina |
| JP2017535545A (ja) * | 2014-11-21 | 2017-11-30 | ラボラトリオス・デル・デエレ・エステベ・エセ・ア | 疼痛に対する多様な活性を有するスピロ−イソキノリン−１，４’−ピペリジン化合物 |
| WO2017137334A1 (en) * | 2016-02-08 | 2017-08-17 | F. Hoffmann-La Roche Ag | Spiroindolinones as ddr1 inhibitors |
| TW202136219A (zh) * | 2019-12-19 | 2021-10-01 | 美商卡司馬療法公司 | Trpml調節劑 |
| CN115867532A (zh) * | 2020-06-12 | 2023-03-28 | 弗特克斯药品有限公司 | Apol1的抑制剂及其用途 |
-
2023
- 2023-02-08 CN CN202380030501.1A patent/CN119212986A/zh active Pending
- 2023-02-08 WO PCT/US2023/012583 patent/WO2023154314A1/en not_active Ceased
- 2023-02-08 AU AU2023218940A patent/AU2023218940A1/en active Pending
- 2023-02-08 EP EP23708332.4A patent/EP4476207A1/en active Pending
- 2023-02-08 CA CA3251155A patent/CA3251155A1/en active Pending
- 2023-02-08 US US18/836,681 patent/US20250195483A1/en active Pending
- 2023-02-08 JP JP2024546423A patent/JP2025505645A/ja active Pending
-
2024
- 2024-09-04 CO CONC2024/0012060A patent/CO2024012060A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US20250195483A1 (en) | 2025-06-19 |
| JP2025505645A (ja) | 2025-02-28 |
| CN119212986A (zh) | 2024-12-27 |
| CA3251155A1 (en) | 2023-08-17 |
| AU2023218940A1 (en) | 2024-08-22 |
| EP4476207A1 (en) | 2024-12-18 |
| WO2023154314A1 (en) | 2023-08-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO2024012060A2 (es) | Derivados de espiro piperidina como inhibidores de apol1 y métodos para usarlos | |
| CO2024012058A2 (es) | Derivados de 2-metil-4’,5’-dihidrospiro[piperidina-4,7’-tieno[2,3-c]pirano] como inhibidores de apol1 y métodos de uso de los mismos | |
| ECSP24050151A (es) | Derivados de 4-fenil-2-(1h-1,2,3-triazol-4-il)piperidin-4-ol como inhibidores de apol1 y métodos para usar los mismos | |
| CL2023000536A1 (es) | Inhibidores de apol1 y métodos para usar los mismos | |
| CO2024001367A2 (es) | Compuestos antivirales | |
| PE20220931A1 (es) | Inhibidores de shp2 fosfatasa de tipo pirazolo[3,4-b]pirazina | |
| UY40474A (es) | Inhibidores heterocíclicos anclados de proteínas kras g12c mutantes y usos de estos | |
| CL2021003202A1 (es) | Compuestos de pirrolidina | |
| PE20190656A1 (es) | Compuestos de tiazolo-piridina sustituida como inhibidores de malt1 | |
| DOP2018000187A (es) | Derivados de pirazolo[1,5-a]pirazin-4-ilo | |
| UY31027A1 (es) | Derivados de tetrahidroindol y tetrahidroindazol | |
| CO2021001277A2 (es) | Inhibidores de triazol glicolato oxidasa | |
| BR112022013488A2 (pt) | Pirazolo-pirimidinas substituídas e seu uso | |
| MX2023014466A (es) | Derivados de piridopirimidina útiles como inhibidores de cinasa wee1. | |
| CO2021017202A2 (es) | Compuestos tricíclicos | |
| CL2025000672A1 (es) | Compuestos derivados de aminopirimidina, inhibidores de cdk2; composición farmacéutica; uso para tratar cáncer. | |
| CO2024010542A2 (es) | Inhibidores de apol1 y métodos de uso | |
| MX2024011755A (es) | Derivados sulfonamidicos como inhibidores de la cinasa dependiente de ciclina 2 (cdk2) | |
| AR126892A1 (es) | Compuestos de aminopiridina sustituidos como inhibidores de egfr | |
| CO2025016753A2 (es) | Inhibidores de gsk3α y métodos de uso de estos | |
| BR112022005706A2 (pt) | Inibidores de 1,6-naftiridina substituída de cdk5 | |
| AR085905A1 (es) | Una combinacion farmaceutica sinergistica para el tratamiento del cancer de pancreas | |
| JOP20240119A1 (ar) | مشتقات نافثيريدينون لمعالجة مرض أو اضطراب | |
| WO2024220852A3 (en) | Tead core inhibitors for cancer therapeutics | |
| EA202192414A1 (ru) | Соединения-ингибиторы натрий-водородного обменника 3 |